Provide feedbackProvide feedback

Home :: Orthopedics

Valeant acquires podiatry-focused pharmaceutical firm

Thursday, April 12 2012 | Comments
Evidence Grade 0 What's This?

Valeant Pharmaceuticals International Inc. purchased Pedinol Pharmacal Inc., a private pharmaceutical company based in Farmingdale, N.Y., that specialized in podiatry products. Valeant said the purchase price was less than 1.5 times sales, adding that Pedinol's revenue last year was approximately $18 million. Reuters reported the purchase price at approximately $27 million. The transaction is expected to be immediately accretive to Valeant. "The Pedinol business will be a strong fit...

Valeant Pharmaceuticals International Inc. purchased Pedinol Pharmacal Inc., a private pharmaceutical company based in Farmingdale, N.Y., that specialized in podiatry products.

Valeant said the purchase price was less than 1.5 times sales, adding that Pedinol's revenue last year was approximately $18 million. Reuters reported the purchase price at approximately $27 million.

The transaction is expected to be immediately accretive to Valeant.

"The Pedinol business will be a strong fit alongside Valeant's dermatology franchise," said J. Michael Pearson, chief executive officer of Valeant. "The podiatry market has similar characteristics to the dermatology market that we find attractive from a risk and reward aspect, and expanding into this area is a natural extension of our topical formulation development capabilities."

Latest News

Auxilium, Actelion enter into partnership to develop, commercialize Xiaflex in certain countries Verusmed

Thursday, February 23 2012 | Comments
Evidence Grade 0 What's This?

Auxilium Pharmaceuticals Inc. and Actelion Pharmaceuticals Ltd. formed a long-term collaboration to develop, supply and commercialize Auxilium's Xiaflex (collagenase clostridium histolyticum), a first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease, in...



Anika Therapeutics licenses U.S. rights to Monovisc to DePuy Mitek Verusmed

Thursday, December 22 2011 | Comments
Evidence Grade 0 What's This?

Anika Therapeutics Inc. entered into an exclusive, multiyear U.S. licensing and supply agreement with DePuy Mitek Inc. for Monovisc (hyaluronic acid), Anika's investigational treatment for pain in patients with osteoarthritis of the knee.

Under the terms of the agreement, Anika will receive an initial payment of $2.5 million and will be...

Tags: Arthritis


Researchers identify factors that appear to influence work interference in study of patients with chronic low back pain Verusmed

Monday, December 19 2011 | Comments
Evidence Grade 0 What's This?

Decreased physical function, daily pain and pain flare-ups all appear to interfere with the ability to work in individuals who have chronic low back pain, based on findings from a prospective study.

The study was conducted in urban family medicine clinics in Texas that provide care to mostly minority, low-income patients.

In all, 360 adults with a diagnosis of chronic low back pain that had persisted for more than three months completed a survey that assessed...



Kai Pharmaceuticals enters into license agreement with Ono Pharmaceutical Verusmed

Monday, December 19 2011 | Comments
Evidence Grade 0 What's This?

Kai Pharmaceuticals Inc. and Ono Pharmaceutical Co. Ltd. established an agreement regarding the development and commercialization of KAI-4169, Kai's lead product candidate, in Japan.

The agreement grants Ono exclusive rights to all indications for injectable formulations of KAI-4169 in Japan. Kai retains commercialization rights elsewhere....





  1. No articles have been read
  1. No articles have been emailed
Videos